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PURPOSE: Tumor-infiltrating lymphocytes (TILs) have an established impact on the prognosis of high-grade
serous ovarian carcinoma (HGSOC), however, their role in recurrent ovarian cancer is largely unknown. We
therefore systematically investigated TIL densities and MHC class I and II (MHC1, 2) expression in the progression
of HGSOC. EXPERIMENTAL DESIGN: CD3+, CD4+, CD8+ TILs and MHC1, 2 expression were evaluated by
immunohistochemistry on tissue microarrays in 113 paired primary and recurrent HGSOC. TILs were quantified by
image analysis. All patients had been included to the EU-funded OCTIPS FP7 project. RESULTS: CD3+, CD4+,
CD8+ TILs and MHC1 and MHC2 expression showed significant correlations between primary and recurrent
tumor levels (Spearman rho 0.427, 0.533, 0.361, 0.456, 0.526 respectively; Pb.0001 each). Paired testing revealedReceived 17 October 2017; Revised 8 January 2018; Accepted 11 January 2018
© 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Neoplasia Vol. 20, No. xx, 2018 Immune Response in Primary and Recurrent HGSOC Stanske et al. 281higher CD4+ densities and MHC1 expression in recurrent tumors (Wilcoxon P=.034 and P=.018). There was also
a shift towards higher CD3+ TILs levels in recurrent carcinomas when analyzing platinum-sensitive tumors only
(Wilcoxon P=.026) and in pairs with recurrent tumor tissue from first relapse only (Wilcoxon P=.031). High MHC2
expression was the only parameter to be significantly linked to prolonged progression-free survival after first
relapse (PFS2, log-rank P=.012). CONCLUSIONS: This is the first study that analyzed the development of TILs
density and MHC expression in paired primary and recurrent HGSOC. The level of the antitumoral immune
response in recurrent tumors was clearly dependent on the one in the primary tumor. Our data contribute to the
understanding of temporal heterogeneity of HGSOC immune microenvironment and have implications for
selection of samples for biomarker testing in the setting of immune-targeting therapeutics.
Neoplasia (2018) 20, 280–288Introduction
Epithelial ovarian cancer (EOC) is one of the most common causes of
gynecological cancer deaths and ranks fifth in the causes of overall
cancer deaths in women. The low 5-year survival rate of 38% can be
attributed to a majority (70%) of the aggressive high-grade serous
ovarian carcinoma (HGSOC) subtype. The poor prognosis of
HGSOC is mainly due to patients being diagnosed in advanced
stage (75% in FIGO III/IV) [1] and to primary or secondary
chemotherapy resistance that develops in almost all patients [2,3].
Cure by radical tumor resection and platinum-based therapy is only
seen in early-stage tumors and rarely in advanced-stage tumors.
Apart from the two most important established prognostic
parameters of tumor stage and residual disease after surgery, the
level of tumor-infiltrating lymphocytes (TILs) has repeatedly been
shown to be a valid prognostic factor for prolonged survival (for meta-
analysis, see [4]). Notably, high numbers of CD3+ and CD8+ TILs
are linked to prolonged survival [5–9]. This applies particularly to
intratumoral lymphocytes, which are in direct contact with tumor
cells and less strongly to stromal lymphocytes [5–7]. Apart from
progression-free and overall survival, the number of TILs may also
affect therapeutic success since tumors with low CD3+ and CD8+
TILs numbers are more likely to be chemoresistant and patients with
low CD8+ TILs benefit from aggressive cytoreduction [10–12].
Cytotoxic T cells (CD8+) are activated by major histocompatibility
complex class I (MHC1) molecules that perform antigen presentation
of aberrant peptides, e.g., viral but also tumoral antigens, while T
helper cells (CD4+) interact with MHC2 molecules that are most
often expressed by antigen-presenting cells. A high expression of
MHC1 and MHC2 in ovarian cancer environment has been found to
correlate with prolonged survival and to be associated with an
increased chemoresponse [10,11,13,14].
These previous findings suggest that the immune system is able to
identify and attack ovarian cancer cells. The inhibition of immune
checkpoints, such as programmed cell death protein 1 (PD1), PD-1
ligand (PD-L1), and cytotoxic T-lymphocyte associated antigen
(CTLA4), was found to mediate cancer regression and prolong
survival in metastatic melanoma and for PD1 blockade also in non–
small cell lung cancer and renal cancer [15–17]. Several clinical trials
on checkpoint inhibitors in EOC are ongoing (for review see, [18]).
Plus, adoptive cell transfer (ACT) has been successfully executed on
metastatic melanoma and showed 50% objective response up to total
tumor regression [19–21] and was also associated with prolongedsurvival in EOC [22,23]. Former trials showed that the tumoral
environment might influence the success of such therapeutics, as for
example a brisk CD8+ TIL expression correlated with a higher
response to PD-1 blockade in melanoma [17].
To fully understand the role of the immune system in HGSOC
and thereby the potential of immunotherapy, a further elucidation of
immunological mechanisms is necessary. In particular, recurrent
HGSOC has not been examined in previous studies; therefore, the
composition of the tumoral microenvironment during cancer
progression remains unanswered. We therefore systematically
investigated the dynamics of tumoral TILs density and MHC class
I and II expression during the progression of HGSOC by analyzing
paired primary and recurrent tumors.
Material and Methods
Patient Cohort and Characteristics
All patients had been included in the OCTIPS project (Ovarian
Cancer Therapy–Innovative Models Prolong Survival, www.octips.eu)
supported by European Community’s Seventh Framework
Programme under grant agreement No. 279113-2. Ethical approval
has been given by the ethics committees of all project partners
(EK207/2003, ML2524, 05/Q0406/178, EK366/2003, EK260/
2003, 06/S1101/16). A total of 158 patients with paraffin-
embedded, formalin-fixed tissue blocks of resection and biopsy
specimens were evaluable. However, in 21 cases, no tumor pair could
be established; 14 turned out not to be HGSOC after histopatho-
logical review, 12 had been treated with neoadjuvant chemotherapy
(not chemonaive) and were excluded from this study. The final study
group included 113 patients with paired samples. Most of the
patients (n=67) were recruited at Charité University Hospital Berlin,
Germany. The other specimens were provided by the OCTIPS
partners University Hospital Leuven, Belgium (n=20); The
University of Edinburgh, United Kingdom (n=16); and London
Imperial College of Science, United Kingdom (n=10). Every
included sample for this study was paired, namely, tissue of primary
and recurrent ovarian cancer. Tissue from the first recurrence was
used for most of the cases (74.3 %). Specimens had been obtained
from 1985 until 2015. Data on 53 patients’ germline and/or tumoral
BRCA status were retrieved from the OCTIPS Consortium database
[24,25] Platinum sensitivity and platinum resistance were defined,
according to the Gynecologic Cancer Intergroup, as a relapse
Table 1. Characteristics of the Study Group
n (%)
Total pairs 113 (100%)
Age
b60 years 76 (67.3)
N60 years 37 (32.7)
Median 55 years
FIGO stage primary
FIGO I 2 (1.8)
FIGO II 6 (5.3)
FIGO III 93 (82.3)
FIGO IV 12 (10.6)
Recurrence used for IHC
1st 98 (86.7)
2nd 6 (5.3)
3rd 7 (6.2)
Other 2 (1.8)
Postoperative residual tumor
None 79 (69.9)
Any 34 (30.1)
First-line chemotherapy
Taxol/carboplatin 88 (77.9)
Other platinum-based 19 (16.8)
Other 6 (5.3)
Platinum sensitivity status after 1st-line treatment
Sensitive 89 (78.8)
Resistant 16 (14.2)
Missing 8
Platinum sensitivity status after 2nd-line treatment a
Sensitive 58 (84.1)
Resistant 11 (15.9)
Missing 29
BRCA germline status
wt 12 (57.1)
BRCA1 mt 7 (33.3)
BRCA2 mt 2 (9.5)
Missing 94
BRCA tumor status (includes germline and somatic mt) b
wt 31 (58.5)
BRCA1 mt 16 (30.2)
BRCA2 mt 6 (11.3)
Missing 60
a First recurrence only
b BRCA status in tumor tissue was identical in all pairs of primary and recurrent tumors.
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chemotherapy, respectively [26]. Recurrence was defined based on
Response Evaluation Criteria In Solid Tumors [27]. Clinicopatho-
logical parameters of the study group are outlined in Table 1.
Immunohistochemistry
Immunohistochemistry was performed on tissue microarrays with
two 1-mm tumor cores per case with a Ventana Discovery XT
autostainer (Ventana Medical Systems, Inc. Tucson, AZ). The
following antibodies were used: CD3 (1:200, Dako Denmark A/S,
Ref. No. A0452), CD4 (1:50, Zytomed, Ref. No. 503-3354), CD8
(1:25, Dako/Denmark, Ref. No. M7103), MHC class 1 (HLA-A, B,
C) (1:6.000, Dako/Denmark A/S, Ref. No. D-226-3), and MHC
class 2 (1:200, MBL, Ref. No. M0746). Diaminobenzidine was used
as a chromogen. Antibody detection and counterstaining were
performed according to the manufacturer's protocols.
Evaluation of TILs
For the evaluation of CD3+, CD4+, and CD8+ TILs density, five
fields for each tumor sample were selected and photographed in 400×
magnification (=high-power field) on scanned slides using the VM
Slide explorer 2.2 (VM Scope, Berlin, Germany). Areas with highdensity of the marker of interest were favored. With the use of ROI
Manager (CognitionMaster, VM Scope), tumoral areas in the high-
power fields were visually discriminated against nontumoral areas (such
as stroma, necrosis) and labeled, enabling the ROIManager to calculate
the pure-tumor area for each case. The count of stained TILs was then
performed automatically with CD3 Quantifier (VM Scope). Only
intratumoral TILs which were in direct contact with tumor cells were
evaluated. Absolute CD3+, CD4+, and CD8+ TILs numbers and
tumor areas were then used to calculate TILs density per 1 mm2 tumor
area. As we had previously seen that cutoff values for a prognostic and
thereby biologically relevant effect of TILs density were in the lower
range [28], we also used a low cutoff for the present study (25%
percentile of TILs count in primary tumor) for categorization of cases in
low- and high-TILs density groups. In a previous study from our group
TILs were assessed in a similar way, except that lymphocytes were
identified and labeled by a trained pathologist instead of the CD3
Quantifier software [28]. To guarantee that automatic TILs detection
was as reliable as the visual method previously performed, comparative
studies using n=209HGSOC showed a very strong correlation between
the data obtained by both methods (Spearman’s rho 0.850, Pb.0001).
Figure 1A shows a representative CD8 stain with annotation by the
CD3 Quantifier software.
Evaluation of MHC1 and MHC2 Expression
The evaluation of MHC1 and MHC2 expression in cancer cells was
performed with VM Slide explorer 2.2 and VM TMA Evaluator (VM
Scope). Two cores per specimen were visually assessed regarding the
percentage of stained tumor cells [0% (0 point), 1%-10% (1 point),
11%-50% (2 points), 51%-80% (3 points), 81%-100% (4 points)] and
the intensity of staining [scored negative (0 point), weak (1 point),
moderate (2 points), strong (3 points)]. Bothwere then summarized to a
semiquantitative immunoreactivity score (IRS). For statistical analysis,
the cases were grouped in low- and high-IRS score classes using a lower-
level cutoff value (IRS3) similarly to the TILs cutoff. Figure 1, B and C
shows representative pictures for MHC1 and MHC2 stainings with
each low and high expression, respectively.
Statistical Evaluation
The IBM SPSS Statistics Version 23.0.0.2 (Armonk, NY) and
GraphPad Prism v.5 (La Jolla, CA) were used for statistical analyses.
Spearman rank test was used for correlations between variables. Due
to the wide distribution of TIL counts especially within high ranges
(positively skewed distribution), we also used lg10 values of TILs
density for some calculations. Associations of paired samples were
examined using Wilcoxon signed ranks test; comparison of groups
was performed with Pearson's χ2 (using Fisher's Exact Test) or
Mann-Whitney test. For survival analysis, the Kaplan-Meyer method
with log-rank test was used. Tests were considered statistically
significant with a P value b.05, regarding 2-sided tests.Results
TILs Densities and MHC Expression Patterns
All TILs subsets (CD3+, CD4+, and CD8+ TILs) could be found
in both primary and recurrent tumors. Informative data on CD3+
TILs were available on 97 tumor pairs. The median number of CD3+
TILs in primary tumors was 158/mm2 (range 0-2.454) and in
recurrences 247/mm2 (range 0-3.550). Data on CD4+ TILs were
available for n=100 pairs with a median number of TILs of 82/mm2
Figure 1. Immunohistochemistry. (A) Representative CD8 stain after annotation by CD3 Quantifier image analysis. Stromal areas have
beenmanually encircled (red) and were not evaluated. (a) Stained lymphocytes are labeled by a thin blue line; (b) same picture as in a, with
annotated lymphocytes shown as blue areas. (B) MHC1 expression in HGSOC. (a) Example of a tumor with low, focal expression; (b)
example of a tumor with strong diffuse expression. A membranous and cytoplasmic expression pattern is evident. (C) MHC2 expression
in HGSOC. (a) Weak and focal expression; single cells with strong expression are intratumoral immune cells (which were not evaluated;
arrows); (b) tumor with diffuse expression with varying intensity revealing a mosaic-like pattern; expression is mainly cytoplasmic in these
examples.
Neoplasia Vol. 20, No. xx, 2018 Immune Response in Primary and Recurrent HGSOC Stanske et al. 283(range 0-2.252) in primary and 153/mm2 (range 0-2.098) in
recurrent tumors. In n=98 pairs with data on CD8+ TILs, the median
number of TILs in primaries was 122/mm2 (range 6-2.221) and in
recurrences 144/mm2 (range 0-2.123; Table 2).
We observed that both MHC1 and MHC2 were expressed on the
membrane and cytoplasm of tumor cells and that expression in bothTable 2. CD3+, CD4+, and CD8+ TILs MHC Class I and Class II Categories in Primary and
Recurrent Tumors
Primary Recurrent Total Fisher’s Exact P (Kappa)
n (%) n (%) n (%) n (%)
CD3 low CD3 high
CD3 low 10 (41.7) 14 (58.3) 24 (100) .059
CD3 high 15 (20.5) 58 (79.5) 73 (100) (0.196)
CD4 low CD4 high
CD4 low 10 (40.0) 15 (60.0) 25 (100) .006
CD4 high 9 (12.0) 66 (88.0) 75 (100) (0.192)
CD8 low CD8 high
CD8 low 10 (41.7) 14 (58.3) 24 (100) .122
CD8 high 18 (24.3) 56 (75.7) 74 (100) (0.092)
MHC1 low MHC1 high
MHC1 low 1 (20.0) 4 (80.0) 5 (100) .262
MHC1 high 5 (5.1) 94 (94.9) 99 (100) (0.137)
MHC2 low MHC2 high
MHC2 low 27 (65.9) 14 (34.1) 41 (100) b.0001
MHC2 high 18 (29.5) 43 (70.5) 61 (100) (0.358)cellular compartments was not easily distinguishable. We therefore
evaluated total cellular MHC expression. For MHC1, n=104 paired
samples were evaluable; forMHC2,n=102.MHC1 expression was strong
and diffuse in most cases; the most frequent IRS was 12 (in both primary
and recurrent tumors), and no sample was completely negative. MHC2
was also expressed in tumor cells, however, in a significantly lower rate than
MHC1; the most frequent IRS being 2 (in both primary and recurrent
tumors), 16 (15.7%) were completely negative (IRS0) in primary and 17
(16.7%) in recurrent tumors (see Table 2 for detailed data).
All immunological factorswere positively correlatedwith each other both
within and across primary and recurrent tumors (Supplementary Table 1).
Pairwise Comparison of TIL Densities and MHC Expression
in Primary and Recurrent Tumors
All TIL subsets were moderately but significantly correlated
between primary and recurrent tumors (CD3: Spearman rho 0.427,
Pb.0001, CD4: Spearman rho 0.533, Pb.0001, CD8: Spearman
rho 0.361, Pb.0001; Supplementary Table 1, Figure 2). Paired
testing (Wilcoxon) showed that CD4+ TIL densities in recurrent
tumors were frequently higher than in their respective primaries (P=
.034). A similar trend was seen for CD3 (P=.077) but not for CD8
(P=.624). Comparing categorized TIL data in primary and recurrent
tumors, it became evident that the vast majority of primary tumors
with a high TIL density also had high TILs in the recurrent tumor
(CD3: 79.5%, CD4: 88.0%, CD8: 75.7%; Table 2). In contrast,
Figure 2. Correlation of TILs levels between primary and recurrent
tumors. (A-C) A moderate, significant correlation between CD3+,
CD4+, and CD8+ TILs density in primary and recurrent tumors is
seen. TILs data were logarithmized to deskew the diagram.
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than low TILs in recurrent tumors (CD3: 58.3%, CD4: 60.0%,
CD8: 58.3%). This correlation was significant for CD4+ TILs (P=
.006), borderline significant for CD3+ (P=.059), and only seen as a
trend for CD8 (P=.122). When using the medians of primary tumor
TILs densities as a cutoff (instead of the 25th percentiles, which, due
to their prognostic effects, we considered as biologically more relevant
[27]), we found similar results; however, the shifts toward high
categories in recurrence were not so pronounced (Supplementary
Table 2): while primaries of low CD3 TILs category had an
approximately 50% chance of either low or high category in the
recurrent tumor, primaries of high CD3 category stayed in the high
category in the recurrent tumor in 73.3%. For CD4 TILs, 60% of
primary low category stayed low in the recurrence, while 80% of
primaries with high TILs stayed high. For CD8, there was a weaker
trend towards a switch to the high category in recurrence. Analyzing
pairs with tissue from first recurrence only, which might be
considered to constitute a more homogeneous group, the shift to
higher TILs levels in relapse samples became significant for CD3 (n=
74, Wilcoxon P=.031) and even more significant for CD4 (n=76,
Wilcoxon P=.014) but not for CD8 (n=76, Wilcoxon P=.286).
MHC1 and MHC2 IRS values in primary tumors significantly
correlated with those in recurrent tumors (Spearman rho 0.456,
Pb.0001, and Spearman rho 0.526, Pb.0001, respectively, Supple-
mentary Table 1). As for the TIL rates, we compared the MHC1 and
MHC2 expression in the tumor pairs. Wilcoxon testing showed a
directed change of MHC1 expression to higher IRS values from
primary to recurrent tissue (P = .018), while no significant change was
seen for MHC2 (P=.803). For further investigation, the data for
MHC intensity were split at the cutoff of 3 to obtain two groups: low
expression (IRS0-2) and high expression (IRS3-12). Similarly to
TILs, high MHC1 expression in primary tumors was linked to high
expression in recurrent tumors (94.9%), and primary tumors with
low MHC1 expression were linked to high expression in recurrent
tumors also (80.0%); however, this was not significant probably due
to a low sample size (n=5) in MHC1 low-expressing tumors (P=.262;
Figure 3D). Increasing the number of MHC1 low-expressing cases by
the use of a higher cutoff point (IRS0-4 vs IRS6-12) resulted in a
significant association (P=.016, Supplemental Table 2). Still, 89.7%
of cases with high MHC1 expression in the primary were also MHC1
high in the recurrent tumor, while 64.7% of cases with low MHC1
expression in the primary were MHC1 high in the relapse sample.
Unlike MHC1, MHC2 status in the primary tumor was strongly
linked to the same expression status in recurrences: 1) Primary with
low MHC2 expression was more likely to have low scores in the
paired recurrent tumor as well (73.8% remained low), and 2) high
MHC2 expression in primary was correlated with high scores in
recurrent tumor (63.4% remained high), indicating that the groups
(low and high expression) remained stable during tumor progression
(Pb.001, Table 2). Analyzing pairs with tissue from first recurrence
only, the trend towards higher MHC1 levels in recurrences was only
of borderline significance (n=98, Wilcoxon P=.072), and the analysis
for MHC2 remained nonsignificant (n=88, Wilcoxon P=.770).
Stratification According to Platinum Sensitivity and BRCA
Status
TILs levels (CD3, CD4, CD8) and MHC1 or MHC2 expression
(IRS) were not significantly associated with platinum sensitivity in
primary tumors (Mann-Whitney PN.1). In recurrent tumors, there
Figure 3. Progression-free survival from first to second recurrence (PFS2) in dependence of TILs levels (A-C) and MHC expression (D, E).
There was a trend towards longer PFS2 in recurrent tumors with high CD4+ TILs densities (B). MHC2 expression was significantly linked
to longer PFS2 in recurrent HGSOC (E).
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platinum-sensitive tumors (after second-line treatment, n=63, Mann-
Whitney P=.067). Analyzing patients with platinum-sensitive status
after first-line treatment only (n=89), paired Wilcoxon testing showed
significantly higher CD4+ TILs and MHC1 levels in recurrent
tumors compared to primaries (P=.010, and P=.015), similarly to the
total study group; however, there was also a significant shift towards
higher CD3+TILs numbers in relapses (P=.026). Interestingly, in
patients with platinum sensitivity after both first- and second-line
therapy (n=45), the effect was even more significant for CD3+ TILs
and CD4+ TILs (both Wilcoxon P=.003) but not for MHC1 or
MHC2 (PN.05). Small sample size (n=16) precluded subgroup
analysis in platinum-resistant tumors.
Combining germline and tumoral BRCA status to two categories,
we obtained n=31 BRCAwt tumors and n=22 BRCAmt tumors.
BRCAmt primaries had higher MHC1 and MHC2 expression levels
as compared to BRCAwt primaries (borderline significance P=.055
and P=.056, respectively; for TILs: PN.1). BRCAmt relapses (first
recurrences only) had a significantly higher expression of MHC1 as
compared to BRCAwt relapses (P=.024; MHC2 and TILs: PN.1).
Explorative paired analysis stratified according to BRCA status
showed higher levels of MHC1 expression in recurrent tumors as
compared to primaries in with wild-type BRCA status as the only
significant result (Wilcoxon P=.026; MHC1 in BRCAmt as well as
MHC2 and TILs in BRCAwt and BRCAmt: PN.05).
Prognostic Effect of TIL Density and MHC Expression
To determine the prognostic impact of TIL density, data were split
as described before. Kaplan-Meier analysis confirmed the previously
reported association between CD3+ and CD8+ TIL rates and longer
progression-free survival after primary diagnosis (PFS1). Patients withCD3+ TILs low primaries had a median survival time of 13.4 months
(standard error 1.1) as opposed to 21.3 months in CD3+ TILs high
tumors (standard error 2.2; Pb.001). For CD8+ TILs, median
survival for patients with primaries of the high category was 20.4
months (standard error 1.1) and was 13.6 months for tumors with
low TILs (standard error 2.8, P=.026, not shown). For CD4+ TILs,
MHC1 and MHC2 expression was not significantly associated with
survival (PN.05, not shown).
Data on progression-free survival after the first recurrence (PFS2)
were available for n=74 tumor pairs (only cases with first recurrence
samples were included). Interestingly, high MHC2 expression in the
recurrent tumor was associated with a longer PFS2 [median survival
12.0 months (standard error 2.4) vs 9.0 months (standard error 0.9),
P=.019, Figure 3E]. No significance was obtained for CD3, CD4,
CD8, and MHC1 expression (Figure 3, A-D).
Discussion
In this study, we compared tumor-infiltrating lymphocytes and MHC
expression in primary and recurrent high-grade serous EOC.We found
that TIL infiltrations and MHC expression levels correlated between
primary and relapse samples, and there was a suggestion that immune
engagement might be elevated in many recurrent tumors.
To our knowledge, this is the first study that analyzed
immunological parameters during ovarian cancer progression. There
are however reports on spatial heterogeneity of TILs in breast cancer
that compared different areas of the primary tumor [29] or primary
tumors with corresponding distant metastases [30]. The authors
described that TILs scores were similar in different primary tumors
regions [29] and that, although TILs rates in primary tumors were
higher than in metastases, the composition of the immunological
infiltrate, as to stromal and intraepithelial TILs and different TILs
286 Immune Response in Primary and Recurrent HGSOC Stanske et al. Neoplasia Vol. 20, No. xx, 2018subpopulations, was comparable in tumor sites [30]. Taking together
these and our findings, it seems that spatial and temporal intratumor
heterogeneity of the immune microenvironment might not be a
major characteristic.
Our findings of a correlation between major subsets of T cells in
primary and recurrent samples are not necessarily predictable. The
manifestations of primary and recurrent HGSC were separated by
months or years, and in addition to the temporal aspect,
chemotherapy may cause tumor evolution, potentially resulting in a
significant change of tumor biology [31]. Temporal heterogeneity has
been shown to occur in several biological levels of cancer, also ovarian
cancer, such as on the genomic level. Transcriptomic or epigenetic
landscapes seem to be more affected by temporal heterogeneity,
which might be explained by the greater fluctuation and instability of
these systems [32]. The immunological microenvironment for sure
also belongs to these fluctuant and flexible systems; however, our data
suggest that the molecular constitution regulating TIL levels in a
tumor site seems rather to be inherent to an individual tumor. MHC1
expression is very likely one of the important factors attracting TILs.
One interesting finding in our study was that—after dichotomization
into low– and high–TIL level categories—cases with a high TIL level
in the primary were more likely to retain high levels in the recurrence
than cases with low TIL levels in the primary. Thus, tumors with
high-level TILs have an immunological constitution that seems to be
more stable during tumor progression. Tumors with low-level TILs in
contrast have a relatively high chance to switch to a higher-level
immunological constitution in the recurrence.
Even more surprising than the detection of a correlation between
primary and recurrent tumor TILs and MHC expression is that there
seems to be a shift towards higher immunogenicity in recurrent
tumors as compared to primaries. This shift was seen for CD4+ TILs
as well as MHC1 expression and, in trend, for CD3+ TILs. Analyzing
more homogeneous groups, such as platinum-sensitive tumors only
or pairs with first recurrences only, this effect for CD3+ TILs even
became significant. However, earlier trials reported that MHC class I
was prone to downregulation to evade immunological elimination in
ovarian cancer and other tumor types; especially advanced disease
stages showed this immunoescape mechanism (for review see,
[33,34]). Therefore, we rather expected the MHC1expression in
recurrent tumors to be lower than in the primaries. However, we did
not find such downregulation during tumor progression in our study
group. On the contrary, the recurrent tumors tended to show higher
expression values than primary lesions, independent of their
expression level in the primary tumor. Thus, the vast majority of
cases with a high expression in the primary retained a high expression
in the relapse sample; however, cases with a low expression in the
primary most often changed to high levels in the recurrence. Similarly
as for TILs, our MHC1 data indicate that the higher immunogenicity
in the primary, the more likely that it will also be high at recurrence.
Interestingly, a recent study on paired pre– and post–neoadjuvant
chemotherapy (NACT) EOC specimens detected an upward shift of
TILs and PD-L1 expression after NACT [35], and a comparable
study reported enhanced IFNγ production by CD4+ TILs and
increased antitumor Th1 gene signatures in omental tumor biopsies
after NACT [36]. Of note, CD8+ TILs densities were not affected by
NACT in the latter study similarly to our data. Lo et al. also found
higher levels of TILs subsets after NACT of HGSOC; however,
interestingly, there were no changes in MHC1 expression in tumor
cells [37]. These data parallel our findings; however, it is unclear if thesame mechanisms account for our data and results from the 2 other
groups since recurrent tumor samples in our study were retrieved
months or years after chemotherapy, while in the latter studies, they
were retrieved immediately after chemotherapy.
The potential reasons for an upward shift of tumor immunoge-
nicity are unclear to date. Hypothetically, during primary tumor
development, the immune system might adapt to the tumor by
generating memory effectors that recognize a tumor recurrence,
which leads to an even more intense, however not necessarily more
effective, reaction to the recurrent tumor tissue in a significant
number of cases. It is also conceivable that the CD4+ TILs we found
to be increased in recurrent tumors might be constituted in the major
part of regulatory cells that inhibit or attenuate the immune reaction.
This is supported by the fact that cytotoxic CD8+ TILs were not
significantly affected by an upregulation during tumor recurrence. Of
note, the shifts towards higher immune effector levels in recurrences
we found were rather subtle, and validations in independent and
preferably larger cohorts are therefore necessary.
A parallel study on OCTIPS samples investigated gene expression
profiling in paired fresh-frozen samples [38]. The authors found
differences in the expression of immune-related genes to be the
predominant distinguishing feature in HGSC and accordingly
grouped the study group as immune-active and immune-silent.
Interestingly, 51% of cases with a silent phenotype in the primary
switched to an active immunological phenotype in the recurrence as
compared to 36% of cases with an active phenotype that switched to
silent. This parallels our findings of a tendency of TIL-high tumors to
remain high in the recurrence. Interestingly, there were no relevant
differences in gene expression between primary and recurrent tumor
samples within the active-active and within the silent-silent groups,
indicating that, in immunologically concordant cases, the phenotypic
constitution remains similar. This on the morphological level is
paralleled by our study.
The relative stability of immunological features during ovarian
cancer progression we detected in this study has implications for the
assessment of immunological biomarkers in histopathological
diagnosis. As immune checkpoint inhibitors such as anti-PD-1 and
anti-PD-L1 antibodies are clinically investigated in many malignan-
cies as well as in EOC [17], the question on which tumor sample to
use for companion diagnostics or translational analyses became quite
urgent. PD-L1 expression and TILs are important candidate markers
in this regard, but of note, they are not validated markers for response
to checkpoint inhibition in EOC yet. Some trials require novel
biopsies for inclusion of patients, which frequently constitute a
problem because of the invasive procedure in often significantly sick
patients. Our data suggest that primary tumor samples that are
available for almost all patients might be used for biomarker analysis;
at least primary tumors with high TIL densities might be considered
sufficient as a decrease in TILs levels is rare in these cases, while in case
of primaries with low TILs levels, a retesting of recurrent samples
might be considered.
In contrast to the well-established prognostic impact of immuno-
logical features in primary HGSOC, the relevance for the recurrent
situation remains unclear. Our data give a hint that certain markers
(MHC2) might have a certain relevance in the relapse situation, too.
TILs, which have an established strong impact on prognosis in the
primary setting, were not prognostic in the recurrence setting.
Interestingly, the lack of a prognostic information of TILs was
reported in ovarian cancer samples post-NACT, too [37]. However,
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our findings on PFS2 in our study and was particularly prone to false-
negative results.
Our study has several strengths and weaknesses. One limitation is
the sample size that hampers especially subgroup analyses, which
might be of interest (e.g., comparison of tumors that change the
immunological class during progression to those that do not or
comparisons of BRCA mutant and wild-type tumors). Unfortunately,
our paraffin-embedded, formalin-fixed study cohort only partially
overlapped with the OCTIPS fresh-frozen cohort, for which several
molecular data are available. Furthermore, our study has no
independent validation cohort. It is however the largest study to
investigate immunological features in paired ovarian cancer samples.
Another limitation is the fact that these patients due to the fact that
surgery was possible in relapse situation are a highly preselected
cohort that might not be representative for all HGSOC, e.g., median
patient age (55 years) was relatively low. Furthermore, due to the
relatively long ascertainment period, changes in treatment (introduc-
tion of taxanes, development of surgical methods) might have
impacted the homogeneity of the study cohort.
As a conclusion, our observations are in line with previous reports.
TILs subgroups andMHCclasses correlatedwith each other, and a higher
immunogenicity was associated with prolonged survival. However, we
made a further step into the investigation of tumor progression in EOC.
Our study showed a connection of the immunologic pattern between
primary and recurrent lesions; especially tumors with a high immuno-
genicity may have a similar molecular composition during relapse.
Exploring and understanding the immunological profile and its
developmentwill provide a basis for the establishment of new therapeutics
in EOC, such as checkpoint inhibitors or adoptive cell transfer. Further
analyses are needed to validate these findings, preferentially as translational
protocols in clinical trials cohorts, where the data could directly be
investigated as to therapy response. Further molecular characterization of
paired tumor samples, e.g., as to clonal evolution, and, e.g., neoantigen
expression with regard to the immunological phenotype, should give
valuable insights into the temporal heterogeneity of mechanisms
regulating the immunological microenvironment.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.01.007.
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